The revolutionary success of mRNA vaccines has firmly established RNA as a powerful platform for therapeutics. Yet, even as the field expands, researchers are keenly aware of the inherent limitations of linear mRNA—its susceptibility to degradation by cellular enzymes and its potential to trigger innate immune responses. For scientists developing next-generation vaccines, cell therapies, and gene-editing tools, the core challenge is finding an RNA molecule that combines the programmability of mRNA with significantly enhanced stability and a more favorable immunological profile. This is the promise of circular RNA (circRNA). Unlike linear mRNA, circRNA forms a covalently closed continuous loop, lacking the free ends (5′ cap and 3′ poly-A tail) that are the primary targets for exonuclease degradation and key triggers for certain immune pathways. This unique structure makes circRNA remarkably stable within cells, resistant to degradation, and capable of prolonged protein expression. Furthermore, its ability to act as a microRNA (miRNA) sponge, regulating gene expression by binding to miRNAs, opens up entirely new therapeutic avenues. However, producing synthetic, exogenous circRNA of sufficient purity and yield is a complex and specialized process, far removed from standard linear RNA synthesis. This is the critical gap filled by exogenous circular RNA synthesis services, which provide researchers and drug developers with access to this transformative molecule. Global Leading Market Research Publisher QYResearch announces the release of its latest report, “Exogenous Circular RNA Synthesis Service – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032” , providing an authoritative and comprehensive analysis of this nascent, rapidly expanding, and potentially revolutionary sector within the life sciences tools market.
The market’s explosive growth trajectory reflects the immense scientific and commercial interest in circRNA. According to QYResearch’s detailed analysis, the global market for Exogenous Circular RNA Synthesis Services was estimated to be worth a substantial US$ 2,069 million in 2024. With circRNA’s advantages over linear mRNA becoming increasingly recognized and its applications in vaccines, cell therapy, and drug discovery expanding, this market is forecast to more than double, reaching a readjusted size of US$ 4,393 million by 2031. This represents a stunning compound annual growth rate (CAGR) of 11.5% during the forecast period of 2025-2031. This is not merely incremental growth; it signals the early-stage build-out of the service infrastructure required to support what could be the next major wave of RNA-based medicines.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4413703/exogenous-circular-rna-synthesis-service
Defining the Molecule and the Service: The Power of the Circle
Circular RNA (circRNA) is a unique class of RNA characterized by its covalently closed loop structure, formed through a process called backsplicing. This structure confers several remarkable properties:
- Exceptional Stability: The absence of free ends makes circRNA highly resistant to exonuclease degradation, the primary pathway for RNA decay. This results in a much longer half-life within cells compared to linear mRNA, enabling sustained production of the encoded protein.
- Reduced Immunogenicity: Linear mRNA, particularly when delivered exogenously, can be recognized by cellular pattern recognition receptors (like RIG-I and TLRs), triggering an innate immune response. The circular structure of circRNA has been shown to evade many of these sensors, leading to lower immunogenicity and potentially safer therapeutic profiles.
- Regulatory Functions: Many naturally occurring circRNAs act as miRNA “sponges.” They contain multiple microRNA response elements (MREs), which can bind to and sequester specific miRNAs, thereby regulating the expression of genes targeted by those miRNAs. Synthetic circRNAs can be engineered to harness this function for therapeutic purposes.
- Cellular Location: CircRNAs are primarily found in the cytoplasm or stored within exosomes, contributing to their stability and potential for intercellular communication.
The synthesis of exogenous circRNA is technically demanding. The service market is segmented by the core method used to create the circular molecule:
- Segmentation by Type (Synthesis Method):
- Chemical Synthesis Method: This involves solid-phase chemical synthesis of a linear RNA precursor, which is then circularized. It is suitable for shorter circRNAs but can be limited by yield and purity for longer sequences.
- Ligase Method: This is a common enzymatic approach. A linear RNA precursor is synthesized (often by in vitro transcription) and then circularized using a specialized RNA ligase enzyme (e.g., T4 RNA ligase). This method can produce longer circRNAs but requires careful optimization to minimize concatemer formation.
- Ribozyme Method: This method harnesses the self-splicing activity of certain intronic sequences (ribozymes). The linear RNA precursor is designed to contain these ribozyme sequences at its ends, which catalyze the circularization reaction during or after transcription, producing a precise, seamless junction.
These synthesized circRNAs are powerful tools for a range of critical applications:
- Drug Discovery: CircRNAs can be used as tools to study gene function, validate targets, and screen for molecules that modulate RNA stability or miRNA interactions.
- Cell Therapy: CircRNA can be used to engineer cells ex vivo, for example, to express therapeutic proteins or chimeric antigen receptors (CARs) for cancer immunotherapy. Its prolonged expression could enhance the potency of cell therapies.
- Vaccine R&D: CircRNA is being explored as a next-generation vaccine platform. Its stability could enable vaccines with longer shelf lives and its ability to produce antigen for extended periods could lead to stronger and more durable immune responses.
- Disease Mechanism: Studying the role of naturally occurring circRNAs in diseases like cancer, neurodegeneration, and cardiovascular disorders is a major area of research, requiring synthetic circRNAs as controls and probes.
Key Market Drivers and Future Development (2025-2031)
The QYResearch report identifies several powerful market trends shaping the industry’s future.
- Advantages Over Linear mRNA for Therapeutics: The fundamental properties of circRNA—enhanced stability and reduced immunogenicity—are its primary market drivers. For therapeutic applications where long-lasting protein expression is desired (e.g., protein replacement, chronic disease treatment) or where avoiding immune activation is critical (e.g., repeat dosing), circRNA offers a compelling advantage over mRNA.
- Expanding Academic and Industrial Research: The field of circRNA biology is relatively young and rapidly expanding. As more research reveals the diverse functions of circRNA in health and disease, the demand for synthetic circRNA as a research tool grows exponentially. This fuels the early-stage market.
- Preclinical and Clinical Pipeline Development: As circRNA-based therapeutics advance from academic labs into preclinical development and early-stage clinical trials, the demand shifts from small-scale research-grade synthesis to larger-scale, high-purity, and eventually GMP-grade material. This progression is a key driver of future market value.
- Technological Advancements in Synthesis and Purification: The methods for producing high-quality circRNA are continuously improving. Innovation is focused on increasing the yield of circularization reactions, developing more efficient purification methods to remove linear precursors and other byproducts, and scaling up production. Service providers with superior technology platforms will have a significant competitive edge.
- Diversification of Applications: Beyond protein expression and miRNA sponges, researchers are exploring other applications for synthetic circRNA, including as scaffolds for assembling biomolecular complexes and as components in synthetic biology circuits. This diversification will open up new markets and use cases.
- Competitive Landscape: A Mix of Global CROs and Specialized Innovators: The market is served by a mix of established life science tools companies and specialized RNA-focused service providers. Key players identified by QYResearch include global leaders like GenScript, Azenta Life Sciences, and VectorBuilder, which have expanded their offerings to include circRNA synthesis. They are joined by specialized innovators, many based in China, such as Guangzhou IGE Biotechnology, Geneseed, CircNova, and Hongene Biotech, which are at the forefront of developing and optimizing circRNA synthesis technologies. This dynamic ecosystem fosters rapid innovation and provides customers with a range of choices in terms of technology, scale, and expertise.
Exclusive Industry Insight: circRNA as a Platform, Not Just a Tool
A critical observation from analyzing this nascent market is that exogenous circRNA is not just another research reagent; it is the foundation for an entirely new therapeutic platform. The combination of stability, low immunogenicity, and the potential for rolling-circle translation (producing multiple copies of a protein from a single RNA molecule) positions circRNA as a potentially superior alternative to mRNA for a wide range of applications. The race is now on to optimize synthesis methods, develop efficient delivery vehicles (like lipid nanoparticles), and demonstrate clinical proof-of-concept. The service providers that can not only synthesize high-quality circRNA but also partner with therapeutic developers to optimize design, scale up production, and navigate regulatory pathways will be the key enablers of this platform and will capture significant long-term value. The circRNA revolution is in its earliest days, and the synthesis service providers are building the essential infrastructure upon which it will be built.
In conclusion, the global exogenous circular RNA synthesis service market is on an explosive growth path, defined by an 11.5% CAGR and a clear trajectory toward a $4.4 billion industry by 2031. For CEOs, R&D leaders, and investors in the biopharmaceutical and life sciences sectors, this market represents a strategic opportunity to invest early in the enabling technology for what could be the next major class of RNA therapeutics, offering solutions with enhanced stability and duration to address a wide range of human diseases.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
